Document Detail

Transdermal administration of oestrogen/progestagen hormone replacement therapy.
MedLine Citation:
PMID:  1967769     Owner:  NLM     Status:  MEDLINE    
The effects of an oestrogen/progestagen transdermal therapeutic system (TTS) were evaluated in sixteen oestrogen-deficient women. The patients applied conventional oestradiol-TTS for 14 days, then two combined norethisterone acetate/oestradiol patches for a further 14 days. The treatment was repeated for five cycles. Ten patients then underwent metabolic studies. One patient had amenorrhoea, but the rest experienced regular withdrawal bleeding which was seldom heavy. Fourteen endometrial biopsy samples were taken during the fifth treatment cycle; none showed proliferative or hyperplastic features. The effects of transdermal norethisterone acetate on symptoms, lipid metabolism, and psychological status were determined by comparing features in the oestrogen-only phase and in the combined phase; the effects were very mild. These preliminary findings show that transdermal progestagen can be successfully administered in hormone replacement therapy to prevent endometrial proliferation while minimising the adverse effects that may be seen with oral administration.
M I Whitehead; D Fraser; L Schenkel; D Crook; J C Stevenson
Related Documents :
18021979 - Operative treatment of endometrial hyperplasia in kidney graft recipients: report of se...
17161119 - Endometrial histology following 1 year of a continuous daily regimen of levonorgestrel ...
12954519 - A multicenter, randomized study of an extended cycle oral contraceptive.
20486879 - A novel regimen of combination transdermal estrogen and intermittent vaginally administ...
19778479 - Effect of different gonadotrophin priming on ivm of oocytes from women with normal ovar...
11334919 - Hydrosalpinx treated with extended doxycycline does not compromise the success of in vi...
18209409 - Vascular access related septicemia in hemodialysis: a focus on bacterial flora and anti...
3992449 - A new approach for the reconstruction of continuity of the alimentary tract after pancr...
23661109 - Current status of minimally invasive esophagectomy for patients with esophageal cancer.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Lancet     Volume:  335     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:  1990 Feb 
Date Detail:
Created Date:  1990-03-13     Completed Date:  1990-03-13     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  310-2     Citation Subset:  AIM; IM    
Academic Department of Obstetrics and Gynaecology, King's College School of Medicine, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Cutaneous
Clinical Trials as Topic
Drug Combinations
Drug Evaluation
Endometrium / drug effects*
Estradiol / administration & dosage*,  adverse effects,  therapeutic use
Estrogen Replacement Therapy / methods*
Menopause* / psychology
Middle Aged
Norethindrone / administration & dosage,  adverse effects,  analogs & derivatives*,  therapeutic use
Reg. No./Substance:
0/Drug Combinations; 38673-38-0/norethindrone acetate; 50-28-2/Estradiol; 68-22-4/Norethindrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Molecular analysis of aldolase B genes in hereditary fructose intolerance.
Next Document:  Sequestration of antibody to Borrelia burgdorferi in immune complexes in seronegative Lyme disease.